Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 3Wilms Tumor 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphedema 1Kidney Neoplasms 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Depression 1Colorectal Neoplasms 1Clinical Stage III Cutaneous Melanoma AJCC v8 1Cicatrix 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Cyclophosphamide 6pembrolizumab 3Filgrastim 3fludarabine 2Nivolumab 2Mesna 2Ipilimumab 2Ifosfamide 2Gemcitabine 2Etoposide 2Docetaxel 2Cryosurgery 2Carboplatin 2tocilizumab 1tipifarnib 1tanespimycin 1poly ICLC 1montanide ISA 51 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1flt3 ligand protein 1entinostat 1dostarlimab 1cc-486 1X-Rays 1Thrombopoietin 1Therapeutics 1Thalidomide 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Absorptiometry, Photon × Dermatologic × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡